AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
-
-
Otsuka and Click Therapeutics announce FDA clearance of Rejoyn, first prescription digital therapeutic for MDD
On Apr. 1, 2024, Otsuka Pharmaceutica and Click Therapeutics announced that the U.S. Food and Drug Administration (FDA)…
-
Results from single-dose psilocybin randomized clinical trial treatment for major depressive disorder published in JAMA
On Aug. 31, 2023, study results published in JAMA found that psilocybin treatment was associated with a clinically…
